Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
about
Science review: natriuretic peptides in critical illnessReducing cardiorenal risk through combination therapy with a direct renin inhibitorEarly neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.Aliskiren and valsartan combination therapy for the management of hypertension.Measurement of the renin-angiotensin system in heart failure.The natriuretic peptides: physiology and role in left-ventricular dysfunction.Cardiac natriuretic peptides--hope or hype?The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.New developments in the pharmacological treatment of chronic heart failure.Inhibitory-excitatory synaptic balance is shifted toward increased excitation in magnocellular neurosecretory cells of heart failure rats.Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormonesNeuroendocrine-autonomic integration in the paraventricular nucleus: novel roles for dendritically released neuropeptides.Vasopressin receptor antagonists in the management of acute heart failure.Altered astrocyte glutamate transporter regulation of hypothalamic neurosecretory neurons in heart failure rats.Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot studyConivaptan: a step forward in the treatment of hyponatremia?Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment.A Functional Coupling Between Carbon Monoxide and Nitric Oxide Contributes to Increased Vasopressin Neuronal Activity in Heart Failure rats.Role of tolvaptan in acute decompensated heart failure.Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialEnhanced NMDA receptor-mediated intracellular calcium signaling in magnocellular neurosecretory neurons in heart failure rats.Emerging diuretics for the treatment of heart failure.Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressureSympathetic neural activity in hypertension and related diseases.Conivaptan: Evidence supporting its therapeutic use in hyponatremia.Significance of hyponatremia in heart failure.Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.New roles for renin and prorenin in heart failure and cardiorenal crosstalk.The role of direct renin inhibition in clinical practice: focus on combination therapy.Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications.Plasma renin and cardiovascular risk: what is the evidence for an association?Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease.Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
P2860
Q24799740-BC68C3B5-C03D-4F35-8651-7CCA8F4A90FDQ26851307-48D12F61-1DE5-4111-BE20-72E9E6A62BAFQ31863980-131E23DF-5AFD-40BE-9F14-5F643A7F3C64Q34139070-7F49A91A-74D4-4645-A2EB-15A2E0698280Q34170513-152573DC-E04F-4E55-BF51-777782835A64Q34171357-EC8D4DCF-3D41-410B-92D9-6C2FDAE72C89Q34207401-96D6E480-A840-4CE5-B46A-52374D15B1B8Q34346282-7DE29933-840B-404D-8A04-19A849A417C5Q34925428-CAC1FD61-E24B-4FB2-B7BD-C596EBF1D400Q35000118-B22D1FF6-BB01-4E47-9B1D-5387BB35F6F2Q35117060-094A3093-6ECC-44EB-BB5E-F578C6BCBD6CQ35217638-10568976-18A5-424D-82A2-F37AB9912533Q35584155-9F54C902-F195-4ECB-8C8D-BE4C3DB1F58EQ35661185-A6ED5B4E-6DD0-418E-B4C0-55451A4031E3Q36145836-F5BFB974-E5AA-4C1D-B00E-C2D4807CE742Q36178516-A3285870-73AD-4A51-AC8F-E0BA6DBFCB62Q36242608-B4E80CFD-5923-4528-8245-147A7FBECBC1Q36351998-EF3312B7-9CD9-48DB-8EFB-884209304620Q36458380-C3F0CE7E-2CE2-41B0-B291-AF5B7E7164D4Q36623035-6F1F64B2-6D30-4507-83B4-9BFCC975A674Q36823541-4C93DCDD-51D8-46A6-AA30-76EADA759200Q36835952-3D98D9BB-E5EE-4A0D-9E6C-C755EDD1E41BQ36911576-C654C984-E7E7-4381-9A97-C250CF7BCD71Q37176415-6919F17B-171C-4B5B-A443-AC374370C207Q37214187-E52A630E-CFBA-4B3E-A998-901DECA83E21Q37323514-2F72399E-9FFA-4401-99EE-4889C1A3FEA8Q37386310-0584EAB2-D43D-4887-A2A7-DA24171AFB6AQ37480881-83C722A0-D9F9-4809-BDB3-61CE0AF1D1B9Q37774849-E3A41113-0855-4361-BD4B-7142CE3B45A2Q37778737-9AB416B3-F381-4C7B-B97F-10FAA380AABAQ37788586-F4CF7184-86A8-41B7-BE1A-C920F226C46EQ37802083-A8843E01-0FC3-4697-89E1-10F0364FC84FQ37893014-1F77BEBE-9613-4E33-B2B9-17818AB19315Q37918526-CF876987-E294-4017-9059-D11821AF20D7Q38005732-16F674CC-29D4-49CC-81CF-9D7498E66DE3Q38007091-449C51D6-F8BB-4165-8469-7C5E0669BB67Q38103400-E979C684-587C-4472-8241-852673650A75Q38208753-2A3FB102-BC96-46F2-8AD6-F8047B9B601DQ38382574-AFC6A4D9-58B1-4745-98DE-29238F6E261BQ39199991-B20E21A6-4615-42B2-80B2-5647EF5A56CC
P2860
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Prognostic value of neurohumor ...... farction: effect of captopril.
@ast
Prognostic value of neurohumor ...... farction: effect of captopril.
@en
Prognostic value of neurohumor ...... farction: effect of captopril.
@nl
type
label
Prognostic value of neurohumor ...... farction: effect of captopril.
@ast
Prognostic value of neurohumor ...... farction: effect of captopril.
@en
Prognostic value of neurohumor ...... farction: effect of captopril.
@nl
prefLabel
Prognostic value of neurohumor ...... farction: effect of captopril.
@ast
Prognostic value of neurohumor ...... farction: effect of captopril.
@en
Prognostic value of neurohumor ...... farction: effect of captopril.
@nl
P2093
P1476
Prognostic value of neurohumor ...... farction: effect of captopril.
@en
P2093
Rouleau JL
Rouleau JR
de Champlain J
P304
P356
10.1016/0735-1097(94)90001-9
P407
P577
1994-09-01T00:00:00Z